Letko, Brosseau & Associates’s MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A MR Stock Holding History

Letko, Brosseau & Associates’s Portfolio MR Stock Details MR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-517,000	Closed	-$14M	–	112
2015 Q4	$14M	Hold	517,000	–	–	0.15%	74
2015 Q3	$11.3M	Hold	517,000	–	–	0.12%	75
2015 Q2	$14.7M	Hold	517,000	–	–	0.14%	72
2015 Q1	$14.1M	Buy	517,000 +285,000	+123%	+$7.85M	0.13%	73
2014 Q4	$6.13M	Hold	232,000	–	–	0.05%	81
2014 Q3	$7M	Buy	232,000 +165,000	+246%	+$5.11M	0.06%	80
2014 Q2	$2.11M	Hold	67,000	–	–	0.02%	84
2014 Q1	$2.17M	Hold	67,000	–	–	0.02%	83
2013 Q4	$2.44M	Hold	67,000	–	–	0.02%	86
2013 Q3	$2.61M	Hold	67,000	–	–	0.02%	82
2013 Q2	$2.51M	Buy	+67,000	New	+$2.65M	0.02%	84

Other funds holding MR

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Letko, Brosseau & Associates's MR Position: Q1 2016 in Review

Letko, Brosseau & Associates sold out of MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A (MR) in Q1 2016, closing a stake of 517,000 shares — an estimated $14M sold.

Letko, Brosseau & Associates first reported a position in MR in Q2 2013 and held it in 11 quarters. The position peaked at $14.7M in Q2 2015. 2 funds tracked by Wall St. Rank hold MR as of Q1 2016.

Letko, Brosseau & Associates reported no remaining MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A position as of Q1 2016 after selling out during the quarter.
Letko, Brosseau & Associates sold 517,000 MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A shares in Q1 2016, an estimated $14M.
Letko, Brosseau & Associates first reported a position in MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A in Q2 2013 and held it in 11 quarters.
Letko, Brosseau & Associates's MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A position peaked at $14.7M in Q2 2015.
2 funds tracked by Wall St. Rank held MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A as of Q1 2016.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2016, filed 11 May 2016.